Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

Affiliations

• ¹ Department of Medicine III, University Hospital, Ludwig Maximilians University, Munich, Germany.
• ² Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA.
• ³ Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany.
• ⁴ Department of Medicine, Washington University, St Louis, Missouri, USA.
• ⁵ Department of Hematology, Infanta Leonor University Hospital, Complutense University, Madrid, Spain.
• ⁶ Janssen Research & Development, Neuss, Germany.
• ⁷ Clinical Biostatistics, Janssen Research & Development, Titusville, New Jersey, USA.
• ⁸ Global Medical Affairs, Janssen Global Services LLC, Raritan, New Jersey, USA.
• ⁹ Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.